Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.74 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448133 | 0.85 | SCN9A (1.00) | SCN9ANPY5RSCN10AFFAR1SCN2A | |
| SCHEMBL14564397 | 0.79 | SCN9A (0.52) | SCN9ASCN10ACFTR | |
| SCHEMBL7823276 | 0.76 | PDK2 (0.57) | SCN9ANR1H2 | |
| SCHEMBL22307353 | 0.71 | SCN9A (0.48) | SCN9ANPY5RSCN10ASCN2A | |
| SCHEMBL3343465 | 0.70 | NOTUM (0.50) | SCN9A | |
| SCHEMBL5934523 | 0.69 | PDK2 (0.49) | CFTR | |
| SCHEMBL4972843 | 0.68 | CFTR (0.58) | ABL1CFTR | |
| SCHEMBL5964032 | 0.66 | OXTR (0.48) | SCN9A | |
| SCHEMBL21609778 | 0.66 | NOTUM (0.57) | SCN9A | |
| SCHEMBL423796 | 0.66 | AKR1C3 (0.62) | SCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060584-A1 | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers | MERCK & CO., INC. | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060584-A1 | Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers | TRPV1, TRPA1, TRPV3 | SCN9A 70/4885NPY5R 635/4885SCN10A 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.